Welcome
| Home | Site Map | Disclaimer
Preliminary Programme
Preliminary Programme
Programme at a glance
Speakers
Invited Speakers - Restricted Area
Skip Navigation LinksHome > Scientific Programme > Preliminary Programme Search:

Preliminary Programme

If you wish to download Preliminary Programme (Uptaded May 19th), click here

Download free Adobe Reader X software to view PDF files. Click here

1.1 MALARIA
1.2 HIV/AIDS, TB AND SEXUALLY TRANSMITTED INFECTIONS (STIS)
1.3 NEGLECTED DISEASES
1.4 VECTOR BORNE DISEASES
1.5 DIARRHOEAL DISEASES
1.6 BACTERIAL DISEASES, PNEUMONIA AND RESPIRATORY INFECTIONS

1.1 MALARIA

1.1.1 Main Session: Advances and challenges in the treatment of malaria

  • The malaria treatment pipeline: Where are we and where are we going?
  • Parenteral artesunate for the treatment of severe malaria and new adjunctive therapies: Implications for European clinicians.
  • The treatment of uncomplicated malaria.  
  • The pharmacokinetics of antimalarial treatment in children and pregnant women.
  • Treatment of malaria at the community level and challenges posed by counterfeit drugs.

1.1.2 Main Session: Vaccines for malaria

  • An update of malaria vaccines development.
  • The RTS,S malaria vaccine’s clinical development: The African perspective.
  • Malaria vaccine immunology.
  • Vaccines for interrupting transmission: Where are we and where are we heading?
  • The European Vaccine Initiative

1.1.3 Parallel Session: Resistance issues in malaria: The parasite and the mosquito.

  • An update of artemisinin resistance in 2011 and its containment efforts
  • Artemisinin resistance in malaria. An old foe, a new challenge
  • Fighting Malaria with engineered bacteria and fungi
  • Insecticide resistance in mosquito vectors: Implications for bednets and IRS strategies
  • Oral Communications

1.1.4 Parallel Session: Global trends in the epidemiology of malaria and advances towards elimination

  • Progress in malaria control and advances towards elimination
  • Changing patterns of malaria in Sub-Saharan Africa
  • Progress towards elimination: Not always a straight path. The Zambian example
  • Highlights of the Malaria Elimination research agenda (MalERA)
  • Oral Communications

1.1.5 Main Session: Host determinants of severity in malaria

  • Are studies on severe malaria still possible, and what can they teach us?
  • The physiopathology of severe malaria
  • Acquisition of immunity against malaria: Are we anywhere near understanding it?
  • Red blood cell polymorphisms and malaria
  • The role of maternal and infant genetics on the acquisition of malaria

1.1.6 Parallel Session: The prevention of malaria

  • Intermittent preventive treatment: A strategy worth not neglecting
  • Cost-effectiveness studies of malaria preventive strategies
  • Bednets for the prevention of malaria: a historical perspective
  • Oral Communications

1.1.7 Parallel Session: Measuring malaria transmission

  • The use of rapid diagnostic tests for measuring malaria transmission
  • Measuring malaria transmission using serology
  • Measuring malaria transmission at the mosquito level
  • Oral communications

1.1.8 Parallel Session: Oral communications on malaria

  • Oral Communications

1.1.9 Main Session: Plasmodium vivax (CRESIB AND CELLEX Foundation)

  • The epidemiology of P. vivax
  • P. vivax malaria during pregnancy
  • Management of P. vivax malaria
  • Severe malaria attributable to P. vivax in Rajasthan, India
  • Autopsic findings in patients with P. vivax malaria who die
  • Vaccines for P. vivax
  • Phase 2a trial system for P. vivax vaccines
  • Molecular approaches to the study of virulence in P. vivax

1.1.10 Main Session. Consensus on malaria prophylaxis (SIMET - Italian Society of Tropical Medicine)

  • Approaching the 'grey areas' on malaria prophylaxis within TropNetEurop through the Delphi method
  • Consensus reached between the French and the Italian Society on 'grey areas' of malaria prophylaxis and remaining controversial issues
  • Invited comment

1.1.11 Satellite Symposium: Dihydroartemisinin/ Piperaquine: advancing and optimizing treatment for uncomplicated malaria (sigma-tau)

Meet the professor: Malaria: What happens if the spleen is absent or hyperreactive

Meet the professor: From the bedside to the bench. How can clinical work in P. vivax influence basic research

Meet the professor: TBD

1.2 HIV/AIDS, TB AND STIs

1.2.1 Main Session: Pre-exposure prophylaxis for HIV prevention 

  • Current advances in microbicides
  • ARVs for pre-exposure prophylaxis (PrEP)
  • Social determinants influencing the use of PrEP

1.2.2 Parallel Session: HIV vaccines and the role of vaccines for HIV positive individuals in the tropics

  • An update in HIV vaccines
  • Progress and hurdles in the development of therapeutic and preventative HIV vaccines
  • HPV vaccines in the developing world
  • EPI programmes in populations with high HIV prevalence
  • Oral Communications

1.2.3 Parallel Session: HIV/TB treatment and care

  • Tuberculosis associated to Immune Reconstruction Inflammatory Syndrome (IRIS)
  • Challenges in IPT administration in latent stage TB infections
  • Improving diagnosis of TB in HIV-infected population
  • Oral Communications

1.2.4 Improving management of TB in the tropics

  • How MDR management can improve general TB control?
  • Treatment outcome of multidrug/extensively drug-resistant TB
  • Oral Communications

1.2.5 Main Session: New Tools for TB: vaccines, drugs and diagnostics

  • Molecular advances in TB and MDR-TB diagnosis (including Gene–Expert and point of care test)
  • Development of new TB drug candidates
  • Current situation of clinical development of TB vaccines
  • New models for drug regimen development. PREDICT-TB consortium

1.2.6 Parallel Session: New strategies for the detection and treatment of STIs in the tropics

  • New diagnostics for STIs
  • Oral Communications

1.2.7 Main Session: Visceral leishmaniasis-HIV co-infection: current challenges and perspectives (Institute of Tropical Medicine Antwerp and DNDi - Drugs for Neglected Diseases Initiative

  • The Mediterranean experience: lessons learned and current challenges
  • Experience from the field
  • VL-HIV co-infection in East-Africa
  • VL-HIV co-infection: emerging in South-America
  • Recent VL-HIV clinical research initiatives in East-Africa

Meet the professor: Chest X-ray interpretation in TB-HIV high-burden settings

Meet the professor: Childhood TB diagnosis and

Meet the professor: Management of HIV associated IRIS in a high-burden area

Meet the professor: TBD

1.3 NEGLECTED DISEASES

1.3.1 Main session: An overview of NTDs

  • The burden and impact of NTDs: An overview
  • Research challenges in NTDs
  • Progress in elimination of NTDs

1.3.2 Main session: Drug development for Kinetoplastids (DNDi - Drugs for Neglected Diseases Initiative)

  • Latest drug development and innovation for kinetoplastids diseases
  • HAT: In-hospital safety of NECT use in African children, pregnant and breast-feeding women
  • New drug candidates and innovation for HAT: From discovery to promising candidates, illustrated by Oxaboroles development
  • Chagas portfolio
  • Treatment modalities for visceral leishmaniasis (Kala-Azar) under field routine program conditions by Médecins sans Frontières

1.3.3 Main Session: The diagnosis and treatment of Leishmaniases (Leti Laboratories)

  • Visceral leishmaniasis elimination initiatives in South East Asia and Brazil
  • Rapid diagnostic tests for Visceral leishmaniasis
  • New perspectives on policies for control of visceral leishmaniasis in India
  • An update of mucocutaneous leishmanisasis
  • New treatments for cutaneous leishmaniasis

1.3.4 Parallel Session: Zoonosis

  • The increase of monkeypox in Africa after the cessation of smallpox vaccination
  • Stage-specific treatment of cystic echinococcosis: Review of the evidence
  • Plasmodium Knowlesi: The (deadly) fifth malaria species
  • Oral Communications

1.3.5 Parallel Session: Human trypanosomiasis

  • Advances and Challenges in the control of Chagas disease
  • New drugs for Chagas: Eisai 1224
  • African trypanosomiasis: current burden of disease and geographical distribution
  • African trypanosomiasis: Neurological aspects
  • Oral Communications

1.3.6 Parallel Session: Schistosomiasis and soil-transmitted helminthiasis

  • Advances in schistosomiasis research
  • Overview of Soil transmitted Helminths/Strongyloidiasis
  • Strongyloides stercolaris control programme in Oran, Argentina
  • New developments with anthelminthic drugs
  • Oral Communications

1.3.7 Parallel Session: Clinical presentation and management of NTDs (I)

  • Control and prevention of Neurocysticercosis
  • Neuroinflammation and brain infections in tropical medicine
  • Oral Communications

1.3.8 Clinical presentation and management of NTDs (II)

  • Advances in Buruli ulcer
  • Oral Communications

1.3.9 Main Session: Improving the quality of diagnostic work-up for neglected tropical diseases, a syndromic approach (NIDIAG Consortium)

  • The need for better quality of diagnostic workup in NTD
  • The neurological syndrome: needs and perspectives on new tests
  • The febrile syndrome: recent advances in antigen detection tests for visceral Leishmaniasis
  • Perspective of health workers

1.3.10 Main Session: How to rise international awareness of Negleted Tropical Diseases (RSTMH - Royal Society of Tropical Medicine and Hygiene)

  • The role of RSTM&H in health policy and advocacy
  • Raising the international profile of schistosomiasis
  • Raising the international profile of podoconiosis
  • Raising the international profile of lymphatic filariasis
  • Discussion

1.3.11 Other issues in NTDs

  • Targetting Wolbachia in the treatment of onchocerchiasis and lymphatic filariasis: Where are we?
  • R+D strategy for a new treatment for filariasis in Loa Loa co-endemic areas
  • Cystic Echinococcosis
  • Oral Communications

Meet the professor: Guinea worm eradication

1.4 VECTOR BORNE DISEASES

1.4.1 Main session: An overview of vector borne diseases

  • An update on arboviral diseases
  • An update on tick borne diseases
  • Flea born diseases: An update on Plague

1.4.2 Main Session: Prevention and control of vector borne diseases: vaccines and vector control

  • Preparedness for Chikungunya and Dengue introduction
  • Vaccines for arboviral diseases
  • Challenges and prospects for 21st century entomologists
  • The prevention of dengue in Mesoamerica

1.4.3 Parallel session: Vector borne diseases

  • Oral Communications

1.4.4 Workshop. Re-introduction of vector borne diseases in the Mediterranean area (SEMTSI - Spanish Society of Tropical Medicine and International Health)

1.4.5 Symposium: The Mesoamerican Health Initiative (SM2015) in vector-borne diseases

  • Malaria and dengue in the Mesoamerican region: a singular transition in global
  • Malaria in Mesoamerica: major achievements and challenges
  • Elimination and control plans for malaria in Mesoamerica
  • Dengue epidemics in an urbanized world

Meet the professor: Yellow fever vaccine-associated viscerotropic

1.5 DIARRHOEAL DISEASES

1.5.1 Parallel session: The global aetiology and epidemiology of pediatric diarrhoeal disease

  • Rotavirus diarrhea
  • The aetiology of pediatric diarrhea in Africa (I). The GEMS study: Clinico-epidemiological considerations
  • The aetiology of pediatric diarrhea in Africa (II). The GEMS study: laboratory aspects
  • Challenges in the management of diarrhea in Latin America, with particular emphasis to the situation in Perú
  • Oral Communications

1.5.2 Parallel session: Cholera update

  • The epidemiology and burden of Cholera
  • Management of cholera
  • Cholera vaccines: State-of-the-art
  • Cholera vaccines: TBD
  • Oral Communications

1.5.3 Parallel Session: Protozoan diseases/Miscellaneous diarrhoea

  • Drug resistance in protozoan diseases: The case of Giardia lamblia
  • Oral Communications

1.6 BACTERIAL DISEASES, PNEUMONIA AND RESPIRATORY INFECTIONS IN THE DEVELOPING

1.6.1 Main session: Pneumonia: World’s number one killer

  • What can we do to reduce the number of pneumonia deaths in children?
  • Effectiveness of pneumonia vaccines
  • Emerging viral pathogens as cause of pneumonia

1.6.2 Parllel session: The global challenge of Influenza pandemics

  • The impact of the H1N1 Influenza A pandemic in a tertiary referral hospital: Predictability, preparedness, and other challenges
  • Influenza Vaccines: An update
  • One Flu – do we need a novel approach to influenza virus infections? 
  • Oral Communications

1.6.3 Parallel session: Antimicrobial resistance and other challenges in the treatment of bacterial infections in the developing world

  • Evolution of antimicrobial resistance in low-income countries
  • Biomarkers in lower respiratory tract infection and sepsis: present and future
  • Surveillance of bacterial resistance in Africa
  • The functioning of pharmaceutical supply chains in developing countries: the example of antibiotics
  • Oral Communications

1.6.4 Parallel session: Sepsis and meningitis in the developing world

  • Non-typhoidal salmonella
  • Misdiagnosis and co-infections between prevalent infectious diseases in Africa
  • Biomarkers for the diagnosis of neonatal sepsis
  • An update on the diagnosis and treatment of meningitis
  • The new vaccine for epidemic meningitis

2.1 MATERNAL, SEXUAL AND REPRODUCTIVE HEALTH
2.2 NEONATAL HEALTH
2.3 CHILDREN’S HEALTH

2.1. MATERNAL, SEXUAL AND REPRODUCTIVE HEALTH

2.1.1 Main session: Maternal Mortality:Evidence of progress?

  • Establishing the causes of maternal mortality in Africa to reduce the burden of maternal deaths
  • Maternal mortality on transition countries in the Maghreb: the Morocco experience
  • Assessing the value of verbal autopsies for determining the cause of maternal deaths
  • The countdown to 2015 for maternal survival: priority interventions to achieve the Millenium Development Goals (MDGs)

2.1.2 Main session: UNSG global strategy for women´s and children´s health. A new global momentum to address MDG 4 and 5

  • UN Women. Promoting human rights in the context of maternal health
  • Delivering on Maternal and Child Health: a consultation on the Joint Action Plan to accelerate MDG 4 and 5
  • Generating knowledge on maternal, reproductive and child health problems, the MARCH Initiative

2.1.3 Symposium: Malaria in Pregnancy Consortium (MiPc)

2.1.4 Main Session: Gender-based violence

  • Feminicide violence in Central America: the Guatemala genocide case
  • The link between female genital mutilation (FGM) and child marriage in Tanzania
  • Sexual violence in the context of migrant, refugee and internally displaced populations

2.1.5 Parallel Session: Maternal, Sexual and Reproductive Health

  • Oral Communications

Meet the professor on maternal health TBD

2.2 NEONATAL HEALTH

2.2.1 Main Session: Global burden and causes of perinatal morbidity and mortality

  • Vertical transmission of non-HIV sexually transmitted infections
  • Delivery of interventions for perinatal survival. Any progress?
  • Stillbirths and pre-term births. Hearing the unheard burden
  • Update and challenges in the prevention of mother-to-child-transmission (PMTCT) of HIV infection

2.3 CHILDREN’S HEALTH
 
2.3.1 Symposium: Nutrition for maternal and children survival. State-of-the-art in malnutrition research

  • Food fortification in children
  • Nutritional Rehabilitation Programs in malnourished children with AIDS and tuberculosis
  • How to reduce mortality rates as low as 5% among malnourished?

2.3.2 Introducing new vaccines into routine immunization program schedules: challenges and prospects (SPE - Société de Pathologie Exotique)

2.3.3 Parallel Session: Perinatal and Infants Health, Malnutrition

  • Oral Communications

Meet the professor on infant health TBD

3.1 THE GLOBAL EPIDEMIC OF CHRONIC DISEASES
3.2 TOBACCO
3.3 CANCER
3.4 ENVIRONMENTAL HEALTH & CLIMATE CHANGE
3.5 CARDIOVASCULAR DISEASES, DIABETES & OTHER CHRONIC DISEASES
3.6 CLIMATE CHANGE AND HEALTH


3.1 THE GLOBAL EPIDEMIC OF CHRONIC DISEASES

3.1.1 Main Session: The Global Epidemic of Chronic Diseases: In search of integrated solutions

3.2 TOBACCO

3.2.1 Parallel Session: The Global Tobacco Epidemic

  • Oral Communications

3.3 CANCER

3.3.1 Parallel Session: Confronting Cancer as a Global Health Problem

  • Oral Communications

3.4 ENVIRONMENTAL HEALTH

3.4.1 Parallel Session: Environmental health

  • Oral Communications

3.5 CARDIOVASCULAR DISEASES, DIABETES, AND OTHER CHRONIC DISEASES

3.5.1 Parallel Session: The Global Impact of Cardiovascular Diseases, Diabetes and Other Chronic Diseases

  • Oral Communications

3.6 CLIMATE CHANGE AND HEALTH

3.6.1 Main Session: Climate change and health

  • Oral Communications

4.1 HEALTH POLICY AND FINANCING
4.2 INNOVATION AND TECHNOLOGIES FOR GLOBAL HEALTH
4.3 HEALTH SYSTEMS, HUMAN RESOURCES AND ACCESS TO CARE

4.1 HEALTH POLICY AND FINANCING (PLENARY SESSION)

4.2 INNOVATION AND TECHNOLOGIES FOR GLOBAL HEALTH

4.2.1 Main Session: Innovation and technologies for global health

4.2.2 Symposium: Decade of Vaccines Collaboration

4.2.3 Workshop: Diagnostic tools

4.2.4 Parallel Session: Innovation and technologies for global health

  • Oral Communications

4.3 HEALTH SYSTEMS, HUMAN RESOURCES AND ACCESS TO CARE

4.3.1 Main Session: Global Access to Care for Women and Children

4.3.2 Debate: Health system strengthening challenges in middle and low income countries: key questions and challenges

4.3.3 Main Session: Role of Social Determinants of Health for Global Health Governance

4.3.4 Main Session: Human resources for Health crises in rural Africa: the contribution of family medicine (NVTG - Netherlands Society of Tropical Medicine and International Health)

  • Setting the scene
  • Positioning the Family Medicine Approach in Kenya and beyond: a solution to the HRH crisis?
  • Family Physicians in Kenya: Has the new profession landed on fertile grounds?
  • Interaction with the audience: Defining the boundaries of Family Medicine in Africa.

4.3.5 Workshop: German Cooperations in International Health & Tropical Medicine (DTG- German Society of Tropical Medicine and International Health)

  • Research, teaching and partnerships with developing countries
  • Esther Alliance: hospital partnership between Limbe, Cameroon and Rostock, Germany
  • Global health and development
  • Albert Schweitzer and his offspring: irrational philanthropists or dedicated professionals. The role of faith-based organisations in the provision of health

4.3.6 Experiences in promoting and evaluating Sector Wide Approaches. SWAp renewal through the International Health Partnership plus (Be-cause health and GRAP-PA Santé, Belgium)

  • Comparative analysis of two extreme cases: the IHP+ in Mali and Benin
  • IHP+ in the context of a fragile State: the case of DRC
  • SWAP and health system strengthening: the case of Tanzania
  • What results can be expected from the agenda for aid effectiveness, linking field experiences with policy?

4.3.7 Debate: Embracing pluralism: Networks dedicated to improving global health

4.3.8 Main Session: INDEPTH Network presentation

4.3.9 Main Session: Capacity building (EAGHA, European Academic Global Health Alliance )

4.3.10 Main Session: Research in international health (EIHA, Eurolife International Health Alliance)

4.3.11 Main Session: tropEd – Learning together for better health worldwide

  • 15 years of tropEd: what kind of ‘masters’ does the network deliver? Results of an alumni survey of Master Students in International Health
  • Personal outcomes, performance at the workplace and resistance to change – a survey amongst tropEd core course students
  • More than a bulk of topics: characterization of the content areas covered by the tropEd course offers
  • Learning experiences and benefits in the quality assurance process of a higher education network in international health
  • tropEd: a capacity building network for partners in North and South

5.1 GLOBAL POPULATION MOVEMENTS: VISITING FRIENDS AND RELATIVES (VFR), MIGRATORY FLOWS AND PILGRIMAGES
5.2 HEALTH CARE POLICIES and SOCIAL DETERMINANTS OF HEALTH IN MIGRANTS
5.3 INFECTIOUS DISEASES (HIV, TB, CHAGAS DISEASE) AND MENTAL HEALTH IN THE MIGRANT POPULATION
5.4 HEALTH IN CONFLICTS and REFUGEE POPULATION
5.5 TRAVEL MEDICINE

5.1 GLOBAL POPULATION MOVEMENTS: VISITING FRIENDS AND RELATIVES (VFR), MIGRATORY FLOWS AND PILGRIMAGES

5.1.1 Main Session: Migratory flows to Europe in the XXI century

  • Global major migrant pathways: changes and trends over last 10-20 years
  • Trends in migration within Europe
  • A glance to the health of socio economic migrants: From origin to destination

5.1.2 Main Session: Migration and Health (NFGHR- Norwegian Forum for Global Health Research)

  • Diet and lifestyle changes in immigrants from low and middle income countries
  • Potentialities for culturally adopted education program to prevent type 2 diabetes in immigrant women in Oslo
  • A visual approach to make lifestyle changes necessary to prevent
  • Treatment of TB with DOT among immigrants in Norway compared to the country of origin- opportunities and challenges
  • Premigration traumatic events and psychological distress among five immigrant groups in Oslo
  • Ethnic differences in musculoskeletal disorders – The Oslo Immigrant Health

5.2 HEALTH CARE POLICIES and SOCIAL DETERMINANTS OF HEALTH IN MIGRANTS

5.2.1 Main Session: Current state of health status of Latin American migrants in Europe

  • Current situation of access to health systems for Latin American migrants in Europe
  • Current state of infectious diseases related to Latin American migrants in Europe: Neglected parasitic diseases and tuberculosis
  • Chronic diseases in the Latin American population
  • Social and Cultural context to health seeking of Latin American migrants in Europe

5.2.2 Parallel Session

  • Oral Communications

5.3 INFECTIOUS DISEASES (HIV, TB, CHAGAS DISEASE) AND MENTAL HEALTH IN THE MIGRANT POPULATION

5.3.1 Workshop: Chagas disease in Europe. Are we doing enough?

  • Preventive measures to avoid transmission of Chagas disease in Europe. What has been done after the Verona meeting?
  • Controlling vertical transmission in Europe. The experience in Catalonia, Spain
  • Chagas disease and blood supplies in Europe

5.3.2 Main Session: Improving HIV management in migrants: Current issues and future challenges.

  • HIV epidemiology and access to testing and care in
  • Opportunistic infections in HIV infected migrants in Europe
  • State of the art of HIV-2 infection

5.3.3 Main Session: Recent advances in epidemiology and management of TB among immigrants in Europe

  • Impact of immigration on the epidemiology of TB in Barcelona
  • Advances in molecular epidemiology: Tracing M. tuberculosis strains
  • Diagnosis and treatment of LTBI in migrants: Is it justified?
  • Case holding of TB in Europe: Does it matter if you are an immigrant?

5.4 HEALTH IN CONFLICTS and REFUGEE POPULATION

5.4.1 Main Session: Future directions of conflict and its consequences

  • Current challenges on providing health in conflict situations
  • The long term health consequences of conflict
  • Chronic diseases in humanitarian crisis: Do the really have a place?

5.5 TRAVEL MEDICINE 

5.5.1 Debate: What are the challenges for European networks in pre and post travel medicine?

5.5.2 Dissertation: The philosophy of travel medicine: Where are we heading?

Meet the professor: Clinical cases in travel medicine I

Meet the professor: Clinical cases in travel medicine II

1. Debate. TBD. FESTMIH, Federation of European Societies for Tropical Medicine and International Health)

2. EU support for partnership in international health research (European Commission - Directorate General for Research)

3. Future research initiatives for better global health (European Commission - Directorate General for Research)

4. Round Table: The role of women in global health research

  • African women and malaria research on the 21st century.
  • Breaking the glass ceiling: proposals to adjust the role of women in science
  • How to achieve gender equity in science

5. Benefits and challenges of community participation in clinical trials. Planeta Salud and The Institute for Global Health of Barcelona- ISGlobal

  • How has improved my essay? Advantages and limitations of community participation from the scientific perspective. Prioritization in R&D policies of results with short-term impact between civil society and accountability of the scientific community in this regard.
  • How does the study affect my community? Advantages and limitations of community participation from the perspective of the community. Community participation as a control mechanism for trials with vulnerable populations.
  • How can we promote community participation from the base? Example of a project to promote community participation in clinical trials in Spain.

6. Main Session: Genome projects: beyond basic research tools? (SSTMP - Swiss Society of Tropical Medicine and Parasitology)

  • Welcome and short introduction
  • Contributions made by the Human Genome Project
  • Contributions made by the Plasmodium sp. Genome Project
  • Contributions made by the Anopheles and Aedes Genome Projects
  • Closing remarks
  • Ethnic differences in musculoskeletal disorders – The Oslo Immigrant Health

7. Workshop: Basic elements and style of attractive scientific texts. TM&IH

8. Workshop: Structure of research papers: AIMRD TM&IH

9. Debate: Media for Science in Global Health

10. Round table: Editor’s conflict of interests

11.Meet the professor: VAPAGuide- The Online emergency guide to venomous and poisonous animals

1. Women’s health: delivering beyond 2015. Challenges and strategies

2. New financing mechanisms for health:  are they making a difference or just complicating the aid architecture?

3. The science of elimination

4. Final Session: Global change, migration and health: the way forward